Skip to main content
Premium Trial:

Request an Annual Quote

ChondroGene Raises $5 million in Private Placement

NEW YORK, Aug. 26 (GenomeWeb News) - Toronto-based ChondroGene announced that it has raised US$5 million in a private placement of 5,263,149 common shares priced at US$.95 per share.


The firm, which trades on the TSX Venture Exchange, is applying functional genomics to the development of biomarkers for diagnostic and therapeutic purposes.


Rodman & Renshaw managed the placement and received $300,000 on the gross proceeds. It also received a warrant entitling the firm to acquire 315,790 shares of ChondroGene at US$.95 per share.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.